Treatment of disease employing hyaluronic acid and nsaids
CA 2061566 C · Owner: Pricewaterhousecoopers Inc. · Inventors: Asculai, Samuel Simon; Falk, Rudolf E.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
A topically applied transdermally penetrating systemic independent acting pharmaceutical combination and formulation for the treatment of a disease or condition of the skin and exposed tissue for example, basal cell carcinoma the, precancerous, often recurrent, actinic keratoses lesions fungal, lesions, "liver" spots and like lesions (found for the most part in the epidermis), squamous cell tumours metastatic cancer of, the breast to the skin primary and metastatic melanoma in the skin, genital warts (condyloma acuminata) cervical cancer and, HPV (Human Papilloma Virus) including HPV of the cervix psoriasis (both plaque-type psoriasis and nail bed psoriasis) corns on the feet and hair loss …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed February 20, 1992 and granted July 9, 2002. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended February 20, 2012.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by February 20, 2014.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.